Want to see CMND full AI Analyst Report?
CMND Stock Chart & Stats
5.94
-0.18(-2.94%)
―
--
Day’s Range― - ―
52-Week Range5.25 - 3,843.46
Previous CloseN/A
VolumeN/A
Average Volume (3M)43.45K
Market Cap
$3.01M
Enterprise Value-11.46M
Total Cash (Recent Filing)$15.93M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-89.20
Shares Outstanding507,404
10 Day Avg. Volume28,879
30 Day Avg. Volume43,449
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)339.13
Price to Sales (P/S)0.00
P/FCF Ratio-85.43
Enterprise Value/Market Cap-3.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit211.10
Enterprise Value/Ebitda1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Capitalization And Lower LeverageImproved equity and much lower leverage provide a stronger financial base for advancing programs over the next several months. This reduces balance-sheet pressure and may preserve strategic flexibility, although it does not eliminate the need to fund ongoing losses.
Expanded Intellectual-property PipelinePublication of a Japanese patent application broadens the company’s intellectual-property estate beyond its core mental-health focus into dyskinesia. If pursued successfully, this can create additional indications and support future licensing or development options, though publication itself is not granted protection.
Active Regulatory EngagementSubmitting recommendations to the FDA demonstrates active effort to shape a regulatory pathway for non-hallucinogenic neuroplastogens and at-home use. A clearer pathway could lower supervised-dosing burdens and expand access if regulators adopt such approaches, but the submission is not approval.
Bears Say
No Commercial RevenueZero revenue across annual periods and TTM confirms the business has not yet reached commercial scale. Persistent operating losses mean current activities rely on continued funding rather than internally generated sales, leaving profitability dependent on successful development and eventual commercialization.
Substantial Cash BurnTTM operating cash flow of about -$7.5 million shows substantial ongoing cash consumption. Continued burn can force the company to seek additional capital before programs generate revenue, creating financing pressure and potential dilution even with currently lower leverage.
Reaccelerating LossesThe increase in TTM net loss after improvement through FY2025 suggests operating costs have re-accelerated before the company has established revenue. That weakens near-term earnings visibility and increases reliance on successful clinical execution, funding access, and future commercialization.
Clearmind Medicine News
CMND FAQ
What was Clearmind Medicine’s price range in the past 12 months?
Clearmind Medicine lowest stock price was 5.25 and its highest was 3843.46 in the past 12 months.
What is Clearmind Medicine’s market cap?
Clearmind Medicine’s market cap is $3.01M.
When is Clearmind Medicine’s upcoming earnings report date?
Clearmind Medicine’s upcoming earnings report date is Mar 02, 2027 which is in 131 days.
How were Clearmind Medicine’s earnings last quarter?
Clearmind Medicine released its earnings results on Sep 10, 2026. The company reported -0.573 earnings per share for the quarter.
Is Clearmind Medicine overvalued?
According to Wall Street analysts Clearmind Medicine’s price is currently Undervalued.
Does Clearmind Medicine pay dividends?
Clearmind Medicine does not currently pay dividends.
What is Clearmind Medicine’s EPS estimate?
Clearmind Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clearmind Medicine have?
Clearmind Medicine has 507,404 shares outstanding.
What happened to Clearmind Medicine’s price movement after its last earnings report?
Clearmind Medicine reported an EPS of -0.573 in its last earnings report. Following the earnings report the stock price went down -1.516%.
Which hedge fund is a major shareholder of Clearmind Medicine?
Currently, no hedge funds are holding shares in CMND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clearmind Medicine
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Technical Analysis
Enveric Biosciences
―
Adial Pharmaceuticals
―
Silo Pharma
―
Psyence Biomedical
―
Neuphoria Therapeutics
―
Ownership Overview
―
Insiders
― Other Institutional Investors
99.97% Public Companies and
Individual Investors